The incidence of adenocarcinoma of esophagogastric junction (AEG) has been increasing annually. Due to its unique anatomical location and functional characteristics, the surgical operating space is limited, and the procedure is technically challenging, leading to a relatively high rate of intraoperative and postoperative complications. These issues are particularly pronounced in cases involving higher esophageal invasion. In recent years, with the advancement and maturation of laparoscopic techniques, the procedure of transabdominal hiatal high esophageal transection and anastomosis has been further refined and optimized. This has enabled gastrointestinal surgeons to perform the operation more smoothly, reduce operative time, and decrease the incidence of related complications. By reviewing relevant literatures and summarizing the operational experience of our team, the authors discuss the application value of transabdominal hiatal high esophageal transection and anastomosis in the radical resection of AEG, aiming to improve the success rate of surgery and reduce the incidence of complications.

Intracranial aneurysm is a prevalent cerebrovascular disease,and its rupture can lead to subarachnoid hemorrhage,which is associated with high mortality and morbidity rates.Current treatment modalities for ruptured intracranial aneurysms primarily consist of surgical clipping and endovascular coiling.In recent years,the development and widespread clinical adoption of flow diverter have made these devices a prominent therapeutic option in the treatment of ruptured intracranial aneurysms.This article provides a comprehensive review of the mechanism of flow diverter,the current status of flow diverter implantation in the treatment of ruptured aneurysms,strategies for antiplatelet medication,and innovations in flow diverter materials,aiming to offer a refence for clinical decision-making in the management of ruptured aneurysms.

The coexistence of inflammatory bowel disease(IBD)and autoimmune liver disease(AILD)has gained increasing attention in clinical practice,and there are significant increases in the prevalence rates of autoimmune hepatitis(AIH),primary sclerosing cholangitis(PSC),and AIH-PSC overlap syndrome among the patients with IBD.Several pathogenic mechanisms are shared between IBD and AILDs,including genetic susceptibility,dysregulation of the gut-liver axis,immune imbalance,and abnormal bile acid metabolism.The ECCO guidelines recommend that patients who are suspected of IBD and receive no treatment should undergo a series of liver function tests,including alanine aminotransferase,alkaline phosphatase,gamma-glutamyl transferase,and total serum bilirubin,as well as regular reexaminations during follow-up.While IBD-AILD patients have unique clinical features,there is still a lack of unified diagnosis and treatment guidelines for this comorbidity,and the selection of therapeutic goal often entails a careful balance between the intestinal tract and the liver,requiring interdisciplinary collaboration and combined therapies based on pathogenesis.Future research should focus on the dynamic regulatory networks of the gut-liver axis to develop innovative intervention strategies that ensure both efficacy and safety.

Mechanical thrombectomy,which improves the successful vascular recanalization rate and neurological functional prognosis in patients with acute ischemic stroke(AIS)caused by anterior circulation large vessel occlusion,has become one of the primary therapeutic strategies.Among the pharmacologic adjuvant therapies for mechanical thrombectomy,tirofiban(a platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist)has attracted significant attention due to its antithrombotic mechanism.This article summarized the research progress of tirofiban in the mechanical thrombectomy treatment of AIS patients from the perspectives of pharmacological mechanisms,administration timing,selection of eligible populations,and dosage regimens.It also analyzed the clinical application value and existing controversies of tirofiban,aiming to provide a scientific basis for optimizing the AIS treatment system.

Objective:To construct a sizeable naive human Fab phage display antibody library to screen high-affinity specific antibodies in vitro. Methods:Total RNA was extracted from peripheral blood mononuclear cells (PBMCs) of 126 healthy individuals, subsequently reverse-transcribed into cDNA, and used as a template. PCR amplification was performed to obtain the V H from IgG, IgM and light chain κ, λ, separately, with the initial PCR products serving as templates for a second round of PCR. Overlap extension PCR was employed to generate fragments of the κ and λ light chains. These fragments were ligated with the phage vector pNC3, which harbors the variable region 1 of the heavy chain, to construct a recombinant phage plasmid. This plasmid was then electroporated into competent Escherichia Coli TG1 cells to establish a naive human Fab phage display antibody library. One hundred clones were randomly selected for identification and sequencing, and antibody gene polymorphisms were analyzed using the IMGT database and MAFFT software. Recombinant α-hemolysin from Staphylococcus aureus was utilized to screen Fab antibody fragments through biopanning of the antibody library, followed by random selection of phage ELISA-identified clones. The positive clones (antigen A450∶blank control A450≥2.1) were sequenced. Results:Two large naive Fab phage display antibody libraries were successfully constructed, in which the capacity of κ and λ chain antibody libraries were 1.25×10 11 and 1.54×10 11, respectively. The titers for two antibody libraries were 6.04×10 13 CFU/ml and 3.50×10 13 CFU/ml. The positive transformation insertion rates for κ and λ chain antibody libraries were 96% (96/100) and 100% (100/100), respectively. Sequence analysis revealed that all antibody sequences were unique. The amino acid sequences in the skeletal region were relatively conserved. In contrast, significant variations in the length of the complementarity determining region (CDR) were found, and the diversity of amino acid sequence of the complementary determining region was high, especially the CDR3. Analysis using the IMGT database indicated that the sequences exhibited a broad distribution across variable-diversity-joining gene families. After six rounds of panning, specific phage antibodies enrichment targeting α-hemolysin were achieved. A total of 142 monoclonal antibodies were sequenced, yielding 8 distinct Fab antibody sequences. Conclusion:This study successfully constructed two naive human Fab phage display antibody libraries with large capacity and good diversity, which can be used for screening human antibodies for serum epidemiology.

Objective To evaluate the advantages of powder-liquid double-chamber bag products compared with traditional powder injection. Methods The systematic review method was used to collect the literature on powder-liquid double-chamber bag, extract common evaluation indicators, evaluate the use value of powder-liquid double-chamber bag products, and conduct a comprehensive comparison with traditional powder injection products. Results A total of 23 articles were included in the literature. The effectiveness indicators used for evaluation were the stability of the liquid medicine, the accuracy of the preparation concentration, and the residual amount of the liquid medicine; the safety indicators were the incidence of insoluble particles and the incidence of punctures and scratches. The economic indicators were preparation cost, occupied volume of preparation supplies, waste weight, hospitalization cost and incidence of blood infection. The applicability indicators were preparation time, average occupation of medical staff, packaging weight and storage and transportation volume, environmental adaptability, and ease of waste disposal. Accessibility indicators are the number of manufacturers, raw material supply capacity, and patient affordability. Through the evaluation of literature evidence, it was found that the stability and concentration accuracy of the powder-liquid double-chamber bag were higher than those of the traditional powder injection, and the domestic supply had been achieved. The double-chamber bag method can reduce the infusion reaction and shorten the preparation time of the liquid medicine. Conclusion Compared with traditional powder injectabler products, powder-liquid double-chamber bags have advantages in the dimensions of effectiveness, safety, economy, suitability and innovation, and the accessibility dimension meets the requirements.

Mechanical thrombectomy,which improves the successful vascular recanalization rate and neurological functional prognosis in patients with acute ischemic stroke(AIS)caused by anterior circulation large vessel occlusion,has become one of the primary therapeutic strategies.Among the pharmacologic adjuvant therapies for mechanical thrombectomy,tirofiban(a platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist)has attracted significant attention due to its antithrombotic mechanism.This article summarized the research progress of tirofiban in the mechanical thrombectomy treatment of AIS patients from the perspectives of pharmacological mechanisms,administration timing,selection of eligible populations,and dosage regimens.It also analyzed the clinical application value and existing controversies of tirofiban,aiming to provide a scientific basis for optimizing the AIS treatment system.

Objective:To evaluate the efficacy of lamb′s tripe extract and vitamin B 12 capsule (LTEVB 12C) on chronic atrophic gastritis (CAG) at different locations (antrum lesser curvature, antrum greater curvature, gastric angle, corpus lesser curvature, and corpus greater curvature). Methods:From August 2011 to January 2013, 715 patients with CAG in a multicenter, randomized, double-blind, placebo-controlled trial were enrolled from 16 tertiary first-class hospitals across the country, including the First Affiliated Hospital of Air Force Medical University, Nanfang Hospital of Southern Medical University, the First Hospital of Jilin University, West China Hospital of Sichuan University, etc., there were 476 cases in the LTEVB 12C group and 239 cases in the placebo group. The patients of the LTEVB 12C group received LTEVB 12C, and the patients of placebo group received LTEVB 12C mimetic, all the medications were taken 3 capsules each time and 3 times a day after meals, and the treatment course of 2 groups were both 6 months. The efficacy evaluation criteria included the effective rate (a decrease of ≥1 in histopathological score compared with baseline after 6 months of treatment) and the reversal rate (a decrease of ≥ 2 in histopathological score compared with baseline after 6 months of treatment in the patients with moderate to severe CAG). The impact of lesion sites on the therapeutic effects of LTEVB 12C was analyzed by logistic regression analysis. The two-way unordered Cochran-Mantel-Haenszel chi-square test considering the center effect and Pearson chi-square test were used for statistical analysis. Results:The effective rates of chronic inflammation at the antrum greater curvature and corpus greater curvature (23.3%, 110/473 vs. 13.0%, 31/239; 20.3%, 96/472 vs. 12.6%, 30/239), the effective rates of atrophy at the antrum lesser curvature, antrum greater curvature, gastric angle, corpus lesser curvature, and the corpus greater curvature (27.0%, 118/437 vs. 15.7%, 34/216; 29.2%, 126/432 vs. 18.5%, 38/205; 27.8%, 121/435 vs. 16.7%, 36/216; 32.5%, 127/391 vs. 19.8%, 37/187; 33.0%, 119/361 vs. 21.8%, 39/179), and the effective rates of intestinal metaplasia at the antrum lesser curvature, antrum greater curvature, gastric angle, and the corpus lesser curvature (45.0%, 112/249 vs. 29.8%, 31/104; 53.8%, 86/160 vs. 33.9%, 21/62; 45.8%, 103/225 vs. 24.0%, 25/104; 51.9%, 83/160 vs. 28.3%, 17/60) of the LTEVB 12C group were all higher than those of the placebo group, and the differences were statistically significant ( χ2=10.76, 6.39, 9.69, 7.91, 11.05, 9.62, 8.57, 5.20, 7.11, 12.45, and 6.73; all P<0.05). The reversal rates of chronic inflammation at the corpus lesser curvature and corpus greater curvature (5.2%, 12/231 vs. 0, 0/123; 4.7%, 8/170 vs. 0, 0/88), the reversal rates of atrophy at the antrum lesser curvature, antrum greater curvature, corpus lesser curvature, and the corpus greater curvature (6.8%, 22/323 vs. 1.3%, 2/151; 9.2%, 29/315 vs. 1.4%, 2/144; 14.2%, 38/267 vs. 2.5%, 3/121; 20.8%, 35/168 vs. 5.8%, 4/69), and the reversal rates of intestinal metaplasia at the antrum lesser curvature, antrum greater curvature, gastric angle, and the corpus lesser curvature (29.8%, 39/131 vs. 9.1%, 4/44; 41.0%, 32/78 vs. 12.5%, 3/24; 33.3%, 44/132 vs. 4.8%, 3/63; 50.0%, 37/74 vs. 8.7%, 2/23) of the LTEVB 12C group were all higher than those of the placebo group, and the differences were statistically significant ( χ2=6.58, 5.12, 5.60, 8.61, 11.43, 6.59, 7.30, 4.95, 15.92, 7.62; all P<0.05). There were no statistically significant differences in the effective rates and reversal rates of active inflammation at different locations between the LTEVB 12C group and the placebo group (all P>0.05). The results of logistic regression analysis (taking the antrum lesser curvature as the reference) further confirmed that the reversal rates of chronic inflammation ( OR=0.22, 95% confidence interval (95% CI): 0.07 to 0.67; OR=0.24, 95% CI: 0.07 to 0.80), atrophy ( OR=0.28, 95% CI: 0.16 to 0.49; OR=0.28, 95% CI: 0.16 to 0.49), and intestinal metaplasia ( OR=0.42, 95% CI: 0.24 to 0.77; OR=0.20, 95% CI: 0.08 to 0.52) at the corpus lesser curvature and corpus greater curvature were all higher than those at the antrum lesser curvature, and the differences were statistically significant (all P<0.05). There were no statistically siginificant differences in the reversal rates of the aforementioned pathological features between the antrum greater curvature, gastric angle, and the antrum lesser curvature (all P>0.05). Conclusion:LTEVB 12C can achieve good efficacy in the treatment of CAG, and the chronic inflammation, atrophy, and intestinal metaplasia at multiple locations are improved, especially at the corpus lesser curvature and the corpus greater curvature.

OBJECTIVE To understand the distribution and drug susceptibility rates of clinical Nocardia isolates so as to provide bases for standardized clinical diagnosis and treatment.METHODS The characteristics of clinical dis-tribution of the Nocardia strains that were isolated from The Second Affiliated Hospital of Fujian Medical Univer-sity between Aug.2019 and Aug.2024 were retrospectively analyzed.The isolated strains were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry(MALDI-TOF MS),16S rRNA and rpoB gene sequencing were performed for the strains with low score,and the drug susceptibility testing was carried out by broth micro dilution method.RESULTS Totally 35 strains of Nocardia were isolated from clinical specimens in the five years,11 of which were Nocardia cyriacigeorgica,4 were Nocardia asiatica,3 were No-cardia farcinica,3 were Nocardia brasiliensis,3 were Nocardia sputorum,2 were Nocardia nova,2 were No-cardia otitidiscaviarum,2 were Nocardia beijingensis,2 were Nocardia concava,1 was Nocardia abscessus,1 was Nocardia pseudobrasiliensis,and 1 was Nocardia terpenica.Totally 85.71％of the strains were isolated from lower respiratory tract specimens including sputum,bronchoalveolar lavage fluid,bronchial brushing and lung puncture tissues,and 11.43％were isolated from skin and soft tissues.It was basically same in the male to female ratio for the patients with Nocardia infections,there were 18 cases of male and 17 cases of female.The elderly patients were dominant,and the patients aged more than 60 years old accounted for 51.43％.The strains were mainly isolated from respiratory medicine department and critical care medicine department.The drug sus-ceptibility rates of all the isolated strains to amikacin and linezolid were 100％,the drug susceptibility rates to sul-famethoxazole-trimethoprim were 97.14％,and the drug susceptibility rates to tobramycin,ceftriaxone and imi-penem were 80％,65.71％and 62.86％,respectively;the drug resistance rates to clarithromycin and ciprofloxa-cin were 65.71％and 62.86％,respectively.Among the major species of isolated Nocardia strains,the N.cyri-acigeorgica strains were all sensitive to sulfamethoxazole-trimethoprim,linezolid,tobramycin,amikacin,imipen-em and ceftriaxone,the strains were resistant to ciprofloxacin,and the drug resistance rate to clarithromycin reached up to 81.82％.CONCLUSIONS N.cyriacigeorgica is the predominant species of isolated Nocardia strains.The pulmonary infection is the major type of infection.There is little difference in the male to female ratio among the patients with Nocardia infection,and the elderly patients are dominant.Amikacin,linezolid and sulfame-thoxazole-trimethoprim are the most sensitive drugs,and the drug resistance rates of the stains to clarithromycin are high.

Intracranial aneurysm is a prevalent cerebrovascular disease,and its rupture can lead to subarachnoid hemorrhage,which is associated with high mortality and morbidity rates.Current treatment modalities for ruptured intracranial aneurysms primarily consist of surgical clipping and endovascular coiling.In recent years,the development and widespread clinical adoption of flow diverter have made these devices a prominent therapeutic option in the treatment of ruptured intracranial aneurysms.This article provides a comprehensive review of the mechanism of flow diverter,the current status of flow diverter implantation in the treatment of ruptured aneurysms,strategies for antiplatelet medication,and innovations in flow diverter materials,aiming to offer a refence for clinical decision-making in the management of ruptured aneurysms.